Business
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah.
About this update from Metavia Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah.","length":444,"tagName":"p"},{"type":"image","alt":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","displaySize":"","headline":null,"caption":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":77,"url":"https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oKeVzvlzHhGood7_jpA63w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","width":400,"height":77}},"href":"https://mma.prnewswire.com/media/2568660/MetaVia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also...